Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Noveris Health SciencesMYCOF 19 EPS without NRI is $-0.43 as of Mar. 2026. GuruFocus rates MYCOF with a GF Score™ of 19/100 and a GF Value™ of $0.52 (Significantly Overvalued). Among 790 Drug Manufacturers companies, Noveris Health Sciences ranks better than 96.08% on this metric.
Noveris Health Sciences's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was $-0.01.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.43.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Noveris Health Sciences's EPS without NRI or its related term are showing as below:
MYCOF'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -190.6 Med: 55.4 Max: 80.6
Current: 80.6
MYCOF's 3-Year EPS without NRI Growth Rate is ranked better than 96.08% of 790
companies
in the Drug Manufacturers industry
Industry Median: 9.6
vs MYCOF: 80.60
Noveris Health Sciences (OTCPK:MYCOF) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Noveris Health Sciences EPS without NRI Related Terms
Noveris Health Sciences EPS without NRI Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Noveris Health Sciences's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noveris Health Sciences PE Ratio without NRI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Noveris Health Sciences's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Noveris Health Sciences's PE Ratio without NRI falls into.
Noveris Health Sciences EPS without NRI Calculation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.43
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Noveris Health Sciences (MYCOF) has a EPS without NRI of $-0.43 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Noveris Health Sciences and its competitors. According to the industry distribution chart, Noveris Health Sciences ranks #31 out of 790 companies in the Drug Manufacturers industry, placing it in the top 3.9%.
Is Noveris Health Sciences' EPS without NRI too high?
Noveris Health Sciences' current EPS without NRI is $-0.43. Based on the distribution chart, Noveris Health Sciences ranks #31 out of 790 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Noveris Health Sciences has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noveris Health Sciences' EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Noveris Health Sciences ranks #31 out of 790 companies for EPS without NRI. This places Noveris Health Sciences in the top 4% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.60, based on 790 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Noveris Health Sciences and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noveris Health Sciences's current EPS without NRI is $-0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noveris Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Noveris Health Sciences (MYCOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.52, compared to a current price of $1.10 — trading 111.5% above its estimated fair value. The current EPS without NRI is $-0.43. Noveris Health Sciences' overall GF Score™ is 19/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Noveris Health Sciences (MYCOF), the current EPS without NRI is $-0.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Noveris Health Sciences (MYCOF) Overvalued in 2026?
Based on GuruFocus' analysis, Noveris Health Sciences stock appears to be overvalued.
The current stock price of $1.10 is trading 111.5% above its estimated GF Value™ of $0.52.
GuruFocus considers Noveris Health Sciences to be Significantly Overvalued.
Key valuation signals for MYCOF:
EPS without NRI: $-0.43
GF Value™: $0.52 vs. price of $1.10 (111.5% above fair value)
No single metric tells the full story. See the MYCOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Noveris Health Sciences Inc is a biotech and life sciences company dedicated to developing and commercializing solutions for treating mental health problems and enhancing vitality. The company has a portfolio of patents it is seeking to commercialize, and is exploring opportunities in the stem cell industry. It is developing the next generation of medications and therapies to address mental health disorders such as nicotine addiction and post-traumatic stress disorder (PTSD).
19GF Score
Get the complete analysis for MYCOF
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MYCOF has been successfully added to your 
